Sefunda, a Swiss based company established in early 2019, is a small dedicated team of professionals with background in IVD product development, molecular epidemiology, medical device development and material science combined with operations and business strategy. Sefunda is funded by seed investors.
Increase the safety of patients and promote antibiotic stewardship, while simplifying the technology to maximize our ability to manufacture fast and in large scale.
In the US 30% - 50% of patients receive incorrect antimicrobial treatment, which can in part be attributed to inefficient or incorrect diagnostic processes. Even for the most common infections, the delay between testing and effective treatment can take up to 10 days. A reliable test result often becomes available only after treatment onset. This can lead to serious complications and higher costs for patients, and potentially to accelerating antibiotic resistance worldwide, also known as the slow pandemic.
A Real Time Diagnostics Platform.
Through our rapid, lean and accessible testing platform we make patient-tailored treatment truly accessible and affordable for everybody – delivering immediate actionable results for treatment decision within one single visit. By combining robust, proven and adaptable technology with smart multiplexing capabilities, we bring the precision of a molecular diagnostics lab to your office.
Chlamydia and Gonorrhoeae are the most common notifiable infectious diseases* in the US.
Both Chlamydia and Gonorrhoeae can cause severe reproductive complications and co-infection can lead to a higher transmission rate of HIV. Rapid detection and prompt treatment of patients and partners is detrimental to prevent spreading.
Cephalosporin resistant N. gonorrhoeae is often resistant to multiple classes of antibiotics and is likely to fail empiric treatment. Today the percentage of these strains worldwide hovers around 30% and leaves plenty of leverage for a safe treatment with fluoroquinolones like Ciprofloxacin. However, current guidelines precautionary recommend a dual antibiotic treatment including an injectable drug which represent the last treatment option. As strains resistant to this last resort treatment have already emerged, it is only a matter of time until they take over and render some Gonorrhoeae infections untreatable.
Rapid detection of a curated set of antimicrobial resistant markers can help decide which treatment is safe, effective and has the potential to spare valuable last line treatment options to help delay the spread of untreatable pan resistant N. gonorrhoeae.
(*Chlamydia >1.8 million cases p. a.; Gonorrhoeae > 0.5 million cases p. a.)
Meet the Team
Melanie Schäpers Chief Operating Officer
Katharina Elmer Product Management
Marion Gilsdorf Laboratory Associate
Serej Ley Project Lead
Deniz Tosoni Bioinformatics
Laurin Diener Systems Engineering
Paul Hofer Chief Executive Officer
See what we are up to
Board of Directors
Michael Brück Chairman of the Board
Eric Kübler Member of Board
Board of Advisors
Prof. Dr. med. Dr. phil. Adrian Egli
Adrian Egli Trained at the University of Basel, Switzerland, Adrian holds a MD and a PhD in Clinical Microbiology. Since 2014 he is Research Group Leader, “Applied Microbiology Research” Laboratory, Department of Biomedicine, University Hospital Basel and since 2015 Head of Division, Clinical Microbiology, University Hospital Basel. He also is Secretary of the Personalized Health Cluster on Infectiology, University of Basel and Head of Working Group on Microbiology at Swiss Biobanking Platform.
His current work focuses on:
Developing new diagnostic and screening assays for rapid detection of multidrug resistant and virulent pathogens,
Exploring novel typing technologies such as whole genome sequencing,
Combining phylogenetic tree structures with the impact of individual and herd immunity at various scales using computational models
Understanding pathogen evolution in the context of the host/pathogen/environment interaction
Dr. (MBA) Nicholas Draeger
Nicholas Draeger Nicholas holds a Bsc (Hons) in Chemical Engineering from the University of Natal, South Africa, a PhD from the University of Cambridge, UK, in Biochemical Engineering, and an MBA from the University of Warwick, UK. Nicholas started his career at Roche Pharmaceuticals in Research and later in Global Business Development focusing on M&A and licensing. At the Italian pharmaceutical company, Recordati, he was Director of International Business Development. Later, Nicholas moved into the finance sector at the French finance group, Credit Agricole Indosuez Cheuvreux as head of the Biotech brokerage team. He is co-Founder and Director of Cederberg GmbH, a Swiss pharmaceutical marketing and distribution company, and Founder of Nurevas International, a food (and fortified foods) production and marketing company, with operations in Switzerland and Ghana and with sales across West Africa. Nicholas currently advises a number of international research institutes and young enterprises around the world on entrepreneurship, innovation, strategy, financing and operations. His primary interests lie in healthcare and nutrition.
Prof. Dr. med. vet. Nicole Borel
Nicole Borel Nicole is a DVM and Board-certified Specialist in Veterinary Pathology at the University of Zurich. She is the Head of the National and OIE Reference Laboratory in ovine Chlamydiosis. Since 2013, she is Head of the Division Infection Pathology and since 2020 Associate Professor, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich. Nicole is a member of the Editorial Board, Section Bacteriology of Current Clinical Microbiology Reports, a Member of the international subcommittee for chlamydial taxonomy and part of the Evaluation Board for PostDoc Mobility Fellowships, Domain IIIb (Biology & Medicine), Swiss National Science Foundation (SNSF).
She currently focuses on:
Tetracycline-resistance mechanisms in Chlamydia suis
Co-infection models with Chlamydia and Neisseria
Alterative therapeutic strategies to treat chlamydial infections
Development & validation of new diagnostic tools in molecular pathology
Dipl. Ing. Ralph Hilberath
Ralph Hilberath Academically trained Engineer (Dipl.-Ing.) Biomedical Engineering of Technical University Berlin, Germany. Specialization on biomechanics and implant design. After a career start in a former governmental test institute for medical device in Germany, more than 25 years’ experience in Regulatory Affairs, Regulatory Compliance and Quality Management with international operating Medical Device companies (Biotronik, Guidant, BD and NSF Prosystem), dealing with registration and compliance projects in Europe, US and different other regions worldwide for active implantable and all other risk class and In-vitro medical devices. Experienced member and leader of ISO standardization Medtech Europe working groups.
Prof. Dr. med. Nicola Low
Nicola Low Nicola is an Infectious Disease Epidemiologist, specializing in Sexually Transmitted Infections. She holds an MSc in Communicable Disease Epidemiology from the London School of Hygiene and Tropical Medicine of the University of London, UK, and a MD of the University of Bern, Switzerland. She is Professor of Epidemiology and Public Health and Director of Research at the Institute of Social and Preventive Medicine, University of Bern. She is Deputy editor of Sexually Transmitted Infections, Associate Editor for PLOS Medicine and Secretary General of the International Society for STD Research (ISSTDR).
She currently focuses on:
Epidemiology and prevention of sexually transmitted infections (STI), HIV, and vaccine preventable diseases
Evaluation of screening programmes for Chlamydia trachomatis
MAntimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium
Advocating research integrity and open access publishing
Sefunda is seeking partnership for investments and network building. We are open for discussion concerning amount, future ownership and pricing. Interested? Feel free to call or write an email.